Insider Buying Buzz: Recent posts on X have highlighted significant insider buying at CervoMed Inc. (CRVO), with the CEO, CFO, and a director collectively purchasing over $100,000 in shares. This activity has sparked curiosity among users, as it coincides with key developments in the company’s pipeline.
Clinical Trial Hopes: Discussions on X also focus on upcoming catalysts for CRVO, particularly around FDA alignment for a Phase 3 trial of neflamapimod, a potential treatment for Dementia with Lewy Bodies. Many users express optimism about the clinical data shared recently, viewing it as a pivotal moment for the biotech firm.
Market Speculation: There’s a mix of intrigue and caution on X, with some pointing to a possible financing round on the horizon for CRVO. The stock’s potential is a hot topic, though opinions vary on the risks tied to biotech investments at this stage.
Note: This discussion summary was generated from an AI condensation of post data.
CervoMed Inc. Insider Trading Activity
CervoMed Inc. insiders have traded $CRVO stock on the open market 18 times in the past 6 months. Of those trades, 18 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CRVO stock by insiders over the last 6 months:
- JOHN J ALAM (CEO & President) has made 6 purchases buying 35,000 shares for an estimated $282,651 and 0 sales.
- SYLVIE GREGOIRE has made 6 purchases buying 35,000 shares for an estimated $282,651 and 0 sales.
- MATTHEW WINTON (Chief Commercial and Business) has made 3 purchases buying 15,000 shares for an estimated $117,130 and 0 sales.
- WILLIAM ROBERT ELDER (CFO, GC & Secretary) has made 3 purchases buying 7,000 shares for an estimated $55,290 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CervoMed Inc. Hedge Fund Activity
We have seen 23 institutional investors add shares of CervoMed Inc. stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC removed 65,939 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $533,446
- BLACKROCK, INC. removed 55,217 shares (-53.1%) from their portfolio in Q3 2025, for an estimated $446,705
- MORGAN STANLEY added 38,747 shares (+10.3%) to their portfolio in Q3 2025, for an estimated $313,463
- NUVEEN, LLC removed 34,099 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $214,312
- CITADEL ADVISORS LLC added 30,510 shares (+inf%) to their portfolio in Q3 2025, for an estimated $246,825
- CETERA INVESTMENT ADVISERS added 27,440 shares (+inf%) to their portfolio in Q3 2025, for an estimated $221,989
- SAVVY ADVISORS, INC. added 25,922 shares (+inf%) to their portfolio in Q3 2025, for an estimated $209,708
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CervoMed Inc. Analyst Ratings
Wall Street analysts have issued reports on $CRVO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Roth Capital issued a "Buy" rating on 08/12/2025
- D. Boral Capital issued a "Buy" rating on 08/11/2025
- Chardan Capital issued a "Buy" rating on 08/11/2025
- Canaccord Genuity issued a "Buy" rating on 07/29/2025
To track analyst ratings and price targets for CervoMed Inc., check out Quiver Quantitative's $CRVO forecast page.
CervoMed Inc. Price Targets
Multiple analysts have issued price targets for $CRVO recently. We have seen 5 analysts offer price targets for $CRVO in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $31.0 on 11/11/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $25.0 on 11/05/2025
- Boobalan Pachaiyappan from Roth Capital set a target price of $16.0 on 08/12/2025
- Daniil Gataulin from Chardan Capital set a target price of $15.0 on 08/11/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $27.0 on 07/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
